ArticleFrontiers in nutrition2026
U-shaped relationship of plasma homocysteine with new-onset metabolic dysfunction-associated steatotic liver disease: a cohort study.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD) is defined by hepatic steatosis accompanied by metabolic abnormalities. Prior cross-sectional studies on the association between plasma homocysteine (Hcy) and MASLD, often limited by small sample sizes, have reported conflicting results. Methods: This study included 5,184 adults from the Dalian Health Management Cohort (DHMC; 2014-2023), excluding those with baseline MASLD or severe comorbidities. MASLD was diagnosed using liver ultrasonography and metabolic criteria. Hyperhomocysteinemia (HHcy) was defined as a plasma Hcy level >15 μmol/L. Cox proportional hazards models and restricted cubic spline (RCS) analyses evaluated linear and nonlinear associations between baseline Hcy levels and incident MASLD. Subgroup and sensitivity analyses ensured result robustness. Results: Over a median follow-up of 2.66 years, 1,204 participants developed MASLD. After multivariable adjustment, each standard deviation (SD) increase in Hcy level was associated with a 18% higher risk of incident MASLD (hazard ratio [HR] = 1.18, 95% confidence interval [CI]: 1.11-1.25). Participants with HHcy had a 45% greater risk of developing MASLD compared to those without (HR = 1.45, 95% CI: 1.26-1.68). RCS analysis revealed a U-shaped relationship, with an approximate inflection point around 10 μmol/L identified by restricted cubic spline analysis. Subgroup and sensitivity analyses confirmed these findings. Conclusion: Plasma Hcy levels demonstrated a U-shaped, independent association with the risk of incident MASLD, suggesting that both very low and high concentrations may adversely impact hepatic metabolic health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.